Merck Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non-Small Cell Lung Cancer

September 12, 2014 Merck announced today that its biopharmaceutical division Merck Serono will discontinue the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) as a monotherapy in Stage III non-small cell lung cancer (NSCLC). Luciano Rossetti, Global Head of Research & Development at Merck Serono, said: “While the data from the exploratory subgroup …

Merck Tecemotide Cancer Vaccine Fails Phase II Clinical Trial Goal

Merck’s therapeutic cancer vaccine candidate, tecemotide, has shown no treatment effect in any trial endpoints Merck’s experimental therapeutic cancer vaccine,  in partnership with Oncothyreon,  has recently shown disappointing clinical trial results after the drug failed to meet its primary endpoint, as well as several other secondary endpoints. Many pharmaceutical companies are currently developing therapeutic cancer vaccines, and these are the …

EMD Serono Announces Initiation of Phase III START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer

First patient dosed in tecemotide Phase III trial; study recruiting across 250 sites in over 20 countries START2 builds upon the data from the START* trial and explores the potential of tecemotide in patients with Stage III NSCLC who have demonstrated stable disease or objective response after concurrent chemoradiotherapy April 7, 2014 EMD Serono, Inc., a subsidiary of Merck KGaA, …

Potential Lung Cancer Vaccine Shows Renewed Promise

March 20, 2014 Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted immune response and reduced the number of tumors in mice with lung cancer. The study also found that radiation treatments did not significantly impair the immune response. The paper was published on March 10 in the journal Cancer Immunology Research, an …

Merck goes back to START with lung cancer vaccine

  Like a phoenix rising from the ashes, Merck Serono’s experimental lung cancer vaccine is being revived by the German firm after previously failing a late-stage clinical trial. The previous trial, known as START, failed to provide evidence that the Stimuvax cancer vaccine improved survival, but it seems that insights gleaned from the failure means the therapy isn’t yet dead. …